News
BDRX
4.570
+3.86%
0.170
Biodexa Pharmaceuticals announces result of general meeting
TipRanks · 1d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 1d ago
Weekly Report: what happened at BDRX last week (1111-1115)?
Weekly Report · 5d ago
Biodexa Pharmaceuticals Secures Nasdaq Listing Compliance
TipRanks · 11/12 16:21
Biodexa Pharmaceuticals regains Nasdaq compliance
TipRanks · 11/12 14:10
Weekly Report: what happened at BDRX last week (1104-1108)?
Weekly Report · 11/11 11:19
Biodexa Pharmaceuticals Plans Strategic Share Value Adjustment
TipRanks · 11/07 21:58
Notice of General Meeting
Barchart · 11/07 15:30
Weekly Report: what happened at BDRX last week (1028-1101)?
Weekly Report · 11/04 11:17
Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod
TipRanks · 11/01 21:48
Weekly Report: what happened at BDRX last week (1021-1025)?
Weekly Report · 10/28 11:09
Weekly Report: what happened at BDRX last week (1014-1018)?
Weekly Report · 10/21 11:05
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
Barchart · 10/20 15:00
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 10/17 16:30
Why Is Brain Cancer-Focused Biodexa Pharmaceuticals Stock Trading Lower On Thursday?
Benzinga · 10/17 15:37
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 10/17 12:10
Biodexa Pharmaceuticals releases patient updates on PFS, OS from MAGIC-1 study
TipRanks · 10/17 11:45
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 10/16 16:30
Biodexa Pharmaceuticals plc: Prospectus [Rule 424(b)(3)]
Press release · 10/16 14:36
More
Webull provides a variety of real-time BDRX stock news. You can receive the latest news about Biodexa Pharmaceuticals plc through multiple platforms. This information may help you make smarter investment decisions.
About BDRX
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.